tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Rachel Vatnsdal, 4 are a SELL (17.39%), 8 are a HOLD (34.78%), 11 are a BUY (47.83%).
Analyst Rachel Vatnsdal, currently employed at JPMORGAN, carries an average stock price target met ratio of 65.24% that have a potential upside of 20.98% achieved within 91 days.
Rachel Vatnsdal’s has documented 54 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on HSIC, Henry Schein at 12-Aug-2024.
Analyst best performing recommendations are on MYGN (MYRIAD GENETICS).
The best stock recommendation documented was for MYGN (MYRIAD GENETICS) at 8/7/2023. The price target of $17 was fulfilled within 2 days with a profit of $0.47 (2.69%) receiving and performance score of 13.45.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$0.65
$0.51 (364.29%)
$3.35
1 years 6 months 3 days ago
(18-May-2023)
2/2 (100%)
$0.06 (10.17%)
10
Buy
$1.25
$1.2 (2400.00%)
$19
1 years 6 months 12 days ago
(10-May-2023)
3/4 (75%)
$2.13 (47.39%)
21
Buy
$5
$4.86 (3471.43%)
$30
1 years 8 months 5 days ago
(16-Mar-2023)
7/10 (70%)
$3.68 (278.79%)
819
Hold
$2
$1.86 (1328.57%)
$2.5
1 years 10 months 18 days ago
(03-Jan-2023)
1/2 (50%)
$0.55 (37.93%)
2
Hold
2 years 12 days ago
(09-Nov-2022)
1/2 (50%)
$7.57 (43.43%)
391
Which stock is Rachel Vatnsdal is most bullish on?
Which stock is Rachel Vatnsdal is most reserved on?
What Year was the first public recommendation made by Rachel Vatnsdal?
